Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Serotonin Syndrome × lanreotide × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2 NET 1

Conditions

Neuroendocrine Tumors 12 Carcinoid Tumor 3 Gastro-enteropancreatic neuroendocrine tumor 2 Serotonin Syndrome 1 Neuroendocrine Tumors in Lung 1 Neoplastic Cells, Circulating 1 Gastrointestinal Neoplasms 1 Flushing 1 Diarrhea 1 Carcinoma, Hepatocellular 1 Adenoma, Islet Cell 1

Interventions

telotristat ethyl 2 lanreotide 1 Random Allocation 1 Octreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed

115 enrolled 17 charts

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡